Erasca (NASDAQ:ERAS) vs. eXoZymes (NASDAQ:EXOZ) Head-To-Head Comparison

Erasca (NASDAQ:ERAS) and eXoZymes (NASDAQ:EXOZ) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, valuation, profitability and analyst recommendations.

Earnings and Valuation

This table compares Erasca and eXoZymes”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Erasca	N/A	N/A	-$124.55 million	($0.95)	-19.35
eXoZymes	$70,000.00	765.75	-$9.16 million	($1.19)	-4.89

eXoZymes has higher revenue and earnings than Erasca. Erasca is trading at a lower price-to-earnings ratio than eXoZymes, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Erasca has a beta of 0.66, meaning that its stock price is 34% less volatile than the S&P 500. Comparatively, eXoZymes has a beta of 2.93, meaning that its stock price is 193% more volatile than the S&P 500.

Institutional and Insider Ownership

67.8% of Erasca shares are held by institutional investors. 14.2% of Erasca shares are held by insiders. Comparatively, 72.4% of eXoZymes shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Erasca and eXoZymes’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Erasca	N/A	-38.43%	-32.05%
eXoZymes	N/A	-292.15%	-158.66%

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Erasca and eXoZymes, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Erasca	1	2	8	0	2.64
eXoZymes	1	0	0	0	1.00

Erasca presently has a consensus target price of $22.09, suggesting a potential upside of 20.19%. Given Erasca’s stronger consensus rating and higher possible upside, equities analysts clearly believe Erasca is more favorable than eXoZymes.

Summary

Erasca beats eXoZymes on 7 of the 12 factors compared between the two stocks.

About Erasca

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company’s lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.

About eXoZymes

eXoZymes, Inc. is a development stage synthetic biochemical company. Its synthetic biology platform would enable the scalable exploration of many molecules and properties found in nature. The company was founded by Tyler Korman and Paul Opgenorth in April 2019 and is headquartered in Monrovia, NV.